BIORQ

0.00010.00%
PS

Paul Shabram

Head of Technical Operations

Dr. Paul Shabram, M.B.A., serves as Head of Technical Operations at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since 2022 and served as its Senior Vice President of Technical Operations since April 2022 until 2022, where he is responsible for Manufacturing, Quality Control, Engineering, and Supply Chain teams. He serves as Vice President of Technical Development at PaxVax, Inc. Dr. Shabram served as the Vice President of Operations at PaxVax, Inc. since July 2007. Prior to PaxVax, he held management positions in development and CMC at Schering-Plough/Canji, Cytel, and Chiron. Before joining Progenity, Dr. Shabram formed Ventana BioSciences Consulting to support developers of vaccines and cancer therapeutics. Previously, he was the Vice President of Technical Development at Emergent Biosolutions. Dr. Shabram joined PaxVax in July 2007 where he has established a manufacturing facility fully compliant with Good Manufacturing Procedures (cGMP) and oversees the development of all manufacturing processes from initial vaccine vector to finished product. He has vast biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. During his many years in industry, Dr. Shabram has achieved success in implementing novel manufacturing processes in both the large pharma setting (Schering-Plough) and biotech organizations (Chiron, Cytel, Canji, Arizeke) as well as an independent entrepreneur (Ventana BioSciences, Prototype Design). He has contributed to the CMC sections of fifteen INDs and produced multiple products for 9 clinical trials, one of which, Regranx, was ultimately approved for treatment of diabetic ulcers. Dr. Shabram has been invited to speak at national and international meetings on manufacturing processes in general and adenoviral technologies in particular. He holds a BA in Biochemistry and Molecular Biology from the University of California, Santa Cruz, CA as well as an MBA from the University of Phoenix, and has been a major contributor on 16 publications and 7 patents.

Positions